Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allegion PLC (ALLE) vs Illumina, Inc. (ILMN) Price & Performance

Allegion PLCTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Allegion PLC vs Illumina, Inc. — how do they compare? Allegion PLC trades at $165.82 (market cap $14.32B), while Illumina, Inc. trades at $191.5 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 2× Allegion PLC's market cap, and Allegion PLC pays a 1.26% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

ALLEILMN
Market Cap
$14.32B$29.12B
Sector
IndustrialsHealth
52-Week High
$179.77$205.10
52-Week Low
$125.65$91.00
Enterprise Value
$16.03B$30.48B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allegion PLC

ALLE trades at $166.18, up 0.39% on the day, showing strong momentum following better-than-expected Q2 2026 earnings. The stock demonstrates robust fundamentals with 15.36% net income margin and 33.73% ROE, though recent quarters show mixed earnings performance. Technical indicators suggest bullish momentum with the current price near resistance levels. Recent institutional buying and positive analyst coverage highlight growing confidence in the security products provider's growth trajectory.

Outlook remains positive with raised 2026 guidance and strong Americas segment performance driving optimism. Investment opportunity lies in continued margin expansion and market share gains, while risks include international segment weakness and rising input costs. The stock trades above consensus price target but offers potential upside to high target of $170.

Illumina, Inc.

Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.

The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.

Returns comparison

Trailing returns across standard periods

About Allegion PLC

Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.

Read more on ALLE

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN